The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 354:1186-1188 March 16, 2006 Number 11
NextNext

Natural Killer T Cells and Asthma
A. Barry Kay, M.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Akbari, O.
-PubMed Citation
Invariant natural killer T cells, originally characterized in mice and more recently defined in humans, are a unique, conserved T-cell sublineage possessing a rearrangement of the T-cell antigen receptor (V{alpha}14J{alpha}18 in mice and V{alpha}24J{alpha}18 in humans). Human natural killer T cells also have an invariant beta chain (Vbeta11). V{alpha}24Vbeta11 binds to glycolipids presented by CD1d, a major-histocompatibility complex class I–like molecule expressed on dendritic cells, monocytes, and subgroups of B cells.1 The glycolipid antigens are also highly conserved and include the synthetic glycolipid {alpha}-galactosylceramide, self glycolipids, and glycolipids from bacteria and plant pollens.

The . . . [Full Text of this Article]


Source Information

From the Leukocyte Biology Section, National Heart and Lung Institute, Imperial College, London.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.